Using neuroimaging to individualize TMS treatment for depression: Toward a new paradigm for imaging-guided intervention.

Journal Article

The standard clinical technique for using repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder (MDD) is associated with limited efficacy to date. Such limited efficacy may be due to reliance on scalp-based targeting rather than state-of-the-science methods which incorporate fMRI-guided neuronavigation based on a specific model of neurocircuit dysfunction. In this review, we examine such a specific model drawn from regulatory focus theory, which postulates two brain/behavior systems, the promotion and prevention systems, underlying goal pursuit. Individual differences in these systems have been shown to predict vulnerability to MDD as well as to comorbid generalized anxiety disorder (GAD). Activation of an individual's promotion or prevention goals via priming leads to motivational and affective responses modulated by the individual's appraisal of their progress in attaining the goal. In addition, priming promotion vs. prevention goals induces discriminable patterns of brain activation that are sensitive to the effects of depression and anxiety: MDD is associated with promotion system failure, anhedonic/dysphoric symptoms, and hypoactivation in specific regions in left prefrontal cortex, whereas GAD is associated with prevention system failure, hypervigilant/agitated symptoms, and hyperactivation in right prefrontal cortex (PFC). These left and right PFC locations can be directly targeted in an individualized manner for TMS. Additionally, this individually targeted rTMS can be integrated with cognitive interventions designed to activate the neural circuitry associated with promotion vs. prevention, thus allowing the neuroplasticity induced by the rTMS to benefit the systems likely to be involved in remediating depression. Targeted engagement of cortical systems involved in emotion regulation using individualized fMRI guidance may help increase the efficacy of rTMS in depression.

Full Text

Duke Authors

Cited Authors

  • Luber, BM; Davis, S; Bernhardt, E; Neacsiu, A; Kwapil, L; Lisanby, SH; Strauman, TJ

Published Date

  • March 2017

Published In

Volume / Issue

  • 148 /

Start / End Page

  • 1 - 7

PubMed ID

  • 28062252

Electronic International Standard Serial Number (EISSN)

  • 1095-9572

International Standard Serial Number (ISSN)

  • 1053-8119

Digital Object Identifier (DOI)

  • 10.1016/j.neuroimage.2016.12.083

Language

  • eng